Hefei Starry Gene Biotechnology

Hefei Starry Gene Biotechnology is a clinical-stage biotechnology company focused on developing innovative gene therapies using proprietary AAV vector technology. The company utilizes a high-throughput screening platform and bioinformatics to design tissue-specific AAV capsids with improved transduction efficiency and reduced immunogenicity. Its lead candidate, XY-001, is an AAV-based gene therapy currently being evaluated for the treatment of Hemophilia B. Beyond hematology, Starry Gene is advancing a pipeline of programs targeting ophthalmic and neurological disorders. Founded by experts from the University of Science and Technology of China, the company integrates cutting-edge academic research with industrial drug development. Starry Gene is backed by prominent venture capital firms and is headquartered in the Hefei high-tech industrial development zone.